Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Lindus Health | INDUSTRY |
Not provided
Not provided
Not provided
Diagnostic trial comparing the diagnostic accuracy of the DAYE Diagnostic Tampon (DDT) with a vaginal swab (self-collected and clinician taken).
MAIN STUDY DESIGN
A diagnostic trial comparing the diagnostic accuracy, usability and acceptability of the DAYE Diagnostic Tampon (DDT) compared to standard vaginal self-swabs and clinician administration of a vaginal swabs. Diagnostic accuracy will be compared for detection of Chlamydia, Gonorrhoea, BV & HPV.
A total of 350 eligible participants will be enrolled into the trial in the UK and Italy. To adequately assess DDT performance on specificity and sensitivity, participants will be recruited from one of two groups:
All participants will be randomised according to sample order for the DDT and self-swab using block randomisation:
All eligible participants will be provided with a trial kit containing the DDT and self-swab and attend at least 1 clinic visit as part of their participation in the trial. Participants will also provide answers to questionnaires at baseline and after all sampling is complete.
Participation in the trial is expected to last approximately 2-3 weeks (dependent on timing of clinic appointment(s)). All samples collected during the trial will be sent to a central laboratory for analysis, either in the UK or Italy i.e., samples will be analysed in the country they were collected.
SUB-STUDY DESIGN
A maximum of 210 eligible participants will be recruited and provide 2 samples to a decentralised sub-study to assess the DDTs performance compared to a self-taken vaginal swab. Recruitment will be stopped as soon as 21 positive cases of STI are confirmed by the lab.
All participants will be randomised according to sample order for the DDT and self-swab using block randomisation:
Pre-screening, informed consent, screening and eligibility assessments will occur online. Trial team will confirm e-consent and eligibility. Randomisation will be performed at the point of enrolment by a member of the trial team using a re-generated list of treatment allocation blocks. Some demographic information and medical history will be collected at baseline. All eligible participants will be provided with a trial kit containing the DDT and self-swab which they will use at home and send directly to the testing laboratory. Participants will also provide answers to questionnaires at baseline and after all sampling is complete. Participants will enter data directly into the EDC platform. Participation in the sub-study is expected to last approximately 1 week. All samples collected during the trial will be sent to a central accredited laboratory(s) for analysis in the UK.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm A: Self-swab then DDT | Other | Participants will take the self-swab sample, followed by the DDT sample at home. They will then have the clinician swab taken in the clinic. |
|
| Arm B: DDT then self-swab | Other | Participants will take the DDT sample, followed by the self-swab sample at home. They will then have the clinician swab taken in the clinic. |
|
| Sub-study: Arm A: Self-swab then DDT | Other | Participants will take the self-swab sample, followed by the DDT sample at home. |
|
| Sub-study: Arm B: DDT then self-swab | Other | Participants will take the DDT sample, followed by the self-swab sample at home. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DAYE Diagnostic Tampon | Device | The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746). The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion. |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate the diagnostic accuracy of the Daye Diagnostic Tampon for detecting Chlamydia, Gonorrhea, BV and HPV | Accuracy of the STI, BV and HPV detection using menstrual tampons compared to other specimen collection methods (clinician taken and self-swab) via assays | Within 4 weeks of the samples being received at the lab. |
| Measure | Description | Time Frame |
|---|---|---|
| Assess the usability of the DDT (via After-Scenario Questionnaire - ASQ) | After scenario questionnaire scores - higher scores = more usable | Post-sampling (once all samples are collected) - at study completion usually after 4 weeks |
| Explore participants views of the usability and acceptability of the DDT |
| Measure | Description | Time Frame |
|---|---|---|
| Explore the relationship between duration of wear and diagnostic accuracy. | Duration of DDT wear and diagnostic accuracy | Post sample analysis - 4 weeks after the last samples are received at the lab |
| Sub-study Objective: Evaluate the diagnostic accuracy of the Daye Diagnostic Tampon for detecting STIs (Chlamydia, Gonorrhoea) specifically demonstrating a sensitivity of more than 70% for DDT. |
Inclusion Criteria:
Individuals aged 25-65 years.
People assigned female at birth (AFAB).
Sexually active individuals. In this case, "sexually active" is defined as having penetrative vaginal sex.
Group 1 only: Confirmed HPV+ diagnosis within the past 4 weeks.
a. UK only: Ability to upload evidence of this diagnosis to the trial ePRO system (e.g. via a screenshot of the NHS app, or similar to be reviewed by the trial team).
Willingness to give informed consent and adhere to trial procedures.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Luke Twelves | Lindus Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lindus Health | London | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002690 | Chlamydia Infections |
| D006069 | Gonorrhea |
| D016585 | Vaginosis, Bacterial |
| ID | Term |
|---|---|
| D002694 | Chlamydiaceae Infections |
| D016905 | Gram-Negative Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
Not provided
Not provided
MAIN STUDY:
All participants will have 3 samples taken: DAYE Diagnostic Tampon (DDT), self-swab and clinician administered swab. Participants will be randomised into 2 groups for sampling order between the DDT and self-swab.
SUB-STUDY
In the sub-study will only perform the DDT and self-swab. Participants will be randomised according to sample order for the DDT and self-swab.
Not provided
Not provided
Not provided
Not provided
|
| Vaginal self-swab | Diagnostic Test | A vaginal self-swab typically consists of a long, slender, and flexible stick or handle, often made of plastic or a similar material. At one end, there's a soft, absorbent tip made of cotton or synthetic material. This tip is designed to collect a sample from the vaginal walls or cervix. |
|
| Clinician vaginal swab | Diagnostic Test | A clinician vaginal swab is a medical tool used by healthcare professionals to collect samples from the vaginal canal for diagnostic purposes. It's typically a long, thin, and flexible instrument. At one end, there's a cotton, rayon, or synthetic tip designed to collect cells, discharge, or other materials from the vaginal walls, cervix, or other areas within the vaginal canal. The clinician swab is not taken in sub-study participants. |
|
Quantitative and qualitative feedback from pre- and post-sampling questionnaires |
| Pre-sampling (baseline) and Post-sampling (once all samples are collected) - at study completion usually after 4 weeks |
| Explore participants views of the usability and acceptability of the DDT | Qualitative feedback from focus groups | Through study completion, an average of 4-6 weeks |
| Assess whether the DDT is a preferred sampling method for participants | User preferences (self-report) | Pre-sampling (baseline) and Post-sampling (once all samples are collected) - at study completion usually after 4 weeks |
| Assess if the order of sample collection (self-swab vs DDT) impacts diagnostic accuracy as assessed by assays | Comparison between the detection accuracy of infections between sample order (Group A and Group B) using assays | Post sample analysis - 4 weeks after the last samples are received at the lab |
| willingness to pay | Willingness to pay for the DDT via questions in post-sampling questionnaire | Post-sampling (once all samples are collected) - at study completion usually after 4 weeks |
| Understand the health economic consequences of using the DDT for STI, BV and HPV testing - time taken | Comparison of time taken for DDT vs clinician swab | Post-sampling (once all samples are collected) - at study completion usually after 4 weeks |
| Explore stakeholder attitudes to tampons as a means of sample collection for microbial testing. | Qualitative feedback from stakeholder questionnaires | Throughout the trial (and once stakeholders with a role in the trial have engaged with the tampon) |
| Assess the occurrence of AEs/SAEs as a result of tampon sampling. | AE/SAE occurrence. | None expected, but any events will be collected and recorded on an ongoing basis as outlined in the protocol and analysed at study completion usually after 4 weeks |
Accuracy of the STI detection using menstrual tampons compared to other specimen collection methods (self-swab) via Hologic APTIMA AC assay |
| Samples will be analysed around 2 weeks after collection. The outcome will be assessed as soon as 21 positive samples have been obtained. |
| D007239 | Infections |
| D015231 | Sexually Transmitted Diseases, Bacterial |
| D012749 | Sexually Transmitted Diseases |
| D003141 | Communicable Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D016870 | Neisseriaceae Infections |
| D014627 | Vaginitis |
| D014623 | Vaginal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |